BG105666A - Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complex - Google Patents

Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complex

Info

Publication number
BG105666A
BG105666A BG105666A BG10566601A BG105666A BG 105666 A BG105666 A BG 105666A BG 105666 A BG105666 A BG 105666A BG 10566601 A BG10566601 A BG 10566601A BG 105666 A BG105666 A BG 105666A
Authority
BG
Bulgaria
Prior art keywords
complex
cyclodextrin
beta
ras
sulfobutylether
Prior art date
Application number
BG105666A
Other languages
Bulgarian (bg)
English (en)
Inventor
Krishnaswamy Raghavan
Timothy Malloy
Sailesh Varia
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BG105666A publication Critical patent/BG105666A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
BG105666A 1999-01-21 2001-07-03 Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complex BG105666A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11664799P 1999-01-21 1999-01-21
PCT/US1999/030424 WO2000042849A1 (en) 1999-01-21 1999-12-21 COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-β-CYCLODEXTRIN OR 2-HYDROXYPROPYL-β-CYCLODEXTRIN AND METHOD

Publications (1)

Publication Number Publication Date
BG105666A true BG105666A (en) 2002-04-30

Family

ID=22368422

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105666A BG105666A (en) 1999-01-21 2001-07-03 Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complex

Country Status (33)

Country Link
US (1) US6218375B1 (lt)
EP (1) EP1143796A4 (lt)
JP (1) JP2002535253A (lt)
KR (1) KR100708360B1 (lt)
CN (1) CN1219517C (lt)
AR (1) AR022323A1 (lt)
AU (1) AU772204B2 (lt)
BG (1) BG105666A (lt)
BR (1) BR9916566A (lt)
CA (1) CA2359646C (lt)
CO (1) CO5160253A1 (lt)
CZ (1) CZ20012601A3 (lt)
EE (1) EE200100382A (lt)
GE (1) GEP20043214B (lt)
HK (1) HK1038865A1 (lt)
HU (1) HUP0105160A3 (lt)
ID (1) ID30139A (lt)
IL (1) IL144025A (lt)
LT (1) LT4893B (lt)
LV (1) LV12712B (lt)
MY (1) MY119700A (lt)
NO (1) NO20013585L (lt)
NZ (1) NZ511995A (lt)
PE (1) PE20001419A1 (lt)
PL (1) PL195280B1 (lt)
RU (1) RU2230062C2 (lt)
SK (1) SK9602001A3 (lt)
TR (1) TR200102109T2 (lt)
TW (1) TWI232752B (lt)
UA (1) UA67825C2 (lt)
UY (2) UY25986A1 (lt)
WO (1) WO2000042849A1 (lt)
ZA (1) ZA200104416B (lt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
US6566347B1 (en) * 2001-08-22 2003-05-20 Duquesne University Of The Holy Ghost Controlled release pharmaceutical
WO2003041658A2 (en) * 2001-11-13 2003-05-22 Bristol-Myers Squibb Company Process for the preparation of 3,7-disubstituted-2,3,4,5- tetrahydro-1h-1,4-benzodiazepine compounds
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US6818662B2 (en) * 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
US20040009972A1 (en) * 2002-06-17 2004-01-15 Ding Charles Z. Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ES2708375T3 (es) 2005-09-30 2019-04-09 Lundbeck Pharmaceuticals Llc Nueva formulación parenteral de carbamazepina
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
TW200806284A (en) * 2006-03-31 2008-02-01 Alcon Mfg Ltd Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
MX2009005368A (es) * 2006-11-21 2009-06-05 Novartis Ag Formulacion parenteral estable que contiene un inhibidor de rsv de una estructura de benzodiazepina.
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
PT3106463T (pt) 2008-10-22 2018-05-18 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk
US9023878B2 (en) * 2010-05-26 2015-05-05 Neurophyxia B.V. 2-iminobiotin formulations and uses thereof
WO2012034038A2 (en) * 2010-09-09 2012-03-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dual inhibitors of farnesyltransferase and geranylgeranyltransferase i
US9309203B2 (en) * 2011-10-07 2016-04-12 Pisces Therapeutics, Llc Malignant and non-malignant disease treatment with Ras antagonists
CN105194685A (zh) * 2015-10-15 2015-12-30 重庆大学 磺胺脒的磺丁基醚-β-环糊精包合物及其粉针制剂
DK3389653T3 (da) 2015-12-16 2024-01-02 Neurophyxia B V 2-iminobiotin til anvendelse i behandling af hjernecellelæsion
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
IL304018A (en) 2016-04-04 2023-08-01 Loxo Oncology Inc Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide
ES2952056T3 (es) 2016-05-18 2023-10-26 Loxo Oncology Inc Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US20210145816A1 (en) * 2019-11-15 2021-05-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin
US12479843B2 (en) 2019-12-27 2025-11-25 Soochow University Spiro ring-containing quinazoline compounds
MX2024007452A (es) * 2021-12-15 2024-07-09 Sillajen Inc Composiciones farmaceuticas que comprenden beta-ciclodextrinas modificadas.
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5630927A (en) * 1979-08-24 1981-03-28 Zeria Shinyaku Kogyo Kk Stabilization of guaiazulene and its derivative
US4371673A (en) * 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JPH07165616A (ja) * 1993-12-09 1995-06-27 Hisamitsu Pharmaceut Co Inc シクロデキストリンの複合組成物及び複合化法
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
JPH1067639A (ja) * 1996-08-26 1998-03-10 Shiseido Co Ltd ビタミンｅ−ビタミンｃリン酸ジエステル／シクロデキストリン包接物及び該包接物を配合した皮膚外用剤

Also Published As

Publication number Publication date
AR022323A1 (es) 2002-09-04
HK1038865A1 (zh) 2002-04-04
LT4893B (lt) 2002-02-25
HUP0105160A2 (hu) 2002-05-29
JP2002535253A (ja) 2002-10-22
PE20001419A1 (es) 2001-02-21
SK9602001A3 (en) 2002-06-04
KR100708360B1 (ko) 2007-04-17
EE200100382A (et) 2002-12-16
AU772204B2 (en) 2004-04-22
TR200102109T2 (tr) 2001-12-21
HUP0105160A3 (en) 2003-01-28
ID30139A (id) 2001-11-08
NO20013585L (no) 2001-09-04
LV12712B (en) 2002-01-20
US6218375B1 (en) 2001-04-17
RU2230062C2 (ru) 2004-06-10
PL366338A1 (en) 2005-01-24
CN1219517C (zh) 2005-09-21
CA2359646A1 (en) 2000-07-27
ZA200104416B (en) 2002-05-29
IL144025A0 (en) 2002-04-21
EP1143796A1 (en) 2001-10-17
UY25987A1 (es) 2000-09-29
AU2374000A (en) 2000-08-07
BR9916566A (pt) 2001-11-13
LT2001064A (lt) 2001-10-25
CA2359646C (en) 2008-12-02
LV12712A (lv) 2001-09-20
GEP20043214B (en) 2004-04-26
IL144025A (en) 2004-05-12
PL195280B1 (pl) 2007-08-31
CZ20012601A3 (cs) 2002-05-15
TWI232752B (en) 2005-05-21
NO20013585D0 (no) 2001-07-20
WO2000042849A1 (en) 2000-07-27
UY25986A1 (es) 2000-09-29
MY119700A (en) 2005-06-30
CO5160253A1 (es) 2002-05-30
EP1143796A4 (en) 2002-03-20
UA67825C2 (uk) 2004-07-15
CN1333651A (zh) 2002-01-30
NZ511995A (en) 2003-11-28
KR20010101611A (ko) 2001-11-14

Similar Documents

Publication Publication Date Title
BG105666A (en) Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method for forming the complex
MY118904A (en) 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents
NL300927I1 (nl) tivozanib of een zout of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
MXPA04004037A (es) Compuestos novedosos de 1, 2, 4-de triazol.
NO931433L (no) 4,1-benzoksazepinderivater og deres anvendelse
CA2547947A1 (en) Azole derivatives as active superoxide radical inhibitors
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
TWI266761B (en) Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents
PT1076663E (pt) Derivados funcionalizados de alquilo e alcenilo de cadeia lateral de glicinamidas como inibidores de farnesil transferase
GB2369360A (en) 5-cyano-2-aminopyrimidine derivatives
HUP9802822A2 (hu) Halogén-benzimidazol-származékok, intermedierjeik, előállításuk és a vegyületeket hatóanyagként tartalmazó mikrobicid készítmények
ZA200201831B (en) Quinazoline derivatives.
GB9908410D0 (en) Pyridines
WO2004020430A3 (fr) Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
PL341050A1 (en) Heterocyclic cytoxic agents
YU21100A (sh) Izohinolini kao urokinazni inhibitori
BG103735A (en) Method for the preparation of substituted thiazolidindions
TW350838B (en) Quinoline derivatives
MXPA02003952A (es) Derivados de imidazol como inhibidores de la fosfodieterasa vii.
MY109714A (en) Process for preparing 8-chloroquinolone derivatives
EP0315434A3 (en) Pyridoxal hydrazone derivatives their production and use and pharmaceutical compositions containing the same
BG106048A (en) 6-[[(aryl and heteroaryl)oxy]methyl]naphthalene-2-carboximidamide derivatives, preparation and therapeutic application thereof
AU2002244985A1 (en) Thiazolidinedione derivatives and pharmaceutical composition comprising the same
WO2002033216A3 (en) Corrosion inhibitor-drag reducer combinations
ECSP003322A (es) COMPLEJO DEL INHIBIDOR DE RAS- FARNESIL TRANSFERASA Y SULFOBUTILETER -7-ß- CICLODEXTRINA O 2- HIDROXIPROPIL - ß - CICLODEXTRINA Y METODO